看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 7.7x - 8.5x | 8.1x |
| Selected Fwd EBITDA Multiple | 6.4x - 7.1x | 6.8x |
| Fair Value | $31.78 - $36.05 | $33.92 |
| Upside | 26.5% - 43.5% | 35.0% |
| Benchmarks | Ticker | Full Ticker |
| Assertio Holdings, Inc. | ASRT | NasdaqCM:ASRT |
| Xeris Biopharma Holdings, Inc. | XERS | NasdaqGS:XERS |
| Supernus Pharmaceuticals, Inc. | SUPN | NasdaqGM:SUPN |
| Prestige Consumer Healthcare Inc. | PBH | NYSE:PBH |
| Corcept Therapeutics Incorporated | CORT | NasdaqCM:CORT |
| Amphastar Pharmaceuticals, Inc. | AMPH | NasdaqGS:AMPH |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| ASRT | XERS | SUPN | PBH | CORT | AMPH | ||
| NasdaqCM:ASRT | NasdaqGS:XERS | NasdaqGM:SUPN | NYSE:PBH | NasdaqCM:CORT | NasdaqGS:AMPH | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | -44.5% | NM- | -1.8% | 2.6% | 4.2% | 70.2% | |
| 3Y CAGR | -53.2% | NM- | 8.1% | 4.2% | 3.0% | 39.6% | |
| Latest Twelve Months | -90.3% | 51.1% | 44.3% | -5.0% | 27.2% | 8.7% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 29.3% | -370.0% | 24.4% | 33.6% | 29.8% | 23.9% | |
| Prior Fiscal Year | 35.0% | -19.3% | 16.2% | 33.7% | 22.5% | 36.9% | |
| Latest Fiscal Year | 4.1% | -7.6% | 21.4% | 33.2% | 20.4% | 35.3% | |
| Latest Twelve Months | 4.1% | -7.6% | 21.4% | 32.3% | 20.4% | 35.3% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | -0.01x | 4.30x | 2.10x | 4.46x | 10.27x | 2.13x | |
| EV / LTM EBITDA | -0.3x | -56.4x | 9.8x | 13.8x | 50.3x | 6.0x | |
| EV / LTM EBIT | 0.1x | -31.7x | 22.7x | 15.1x | 50.6x | 7.6x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -56.4x | 9.8x | 50.3x | ||||
| Historical EV / LTM EBITDA | 6.0x | 14.9x | 34.2x | ||||
| Selected EV / LTM EBITDA | 7.7x | 8.1x | 8.5x | ||||
| (x) LTM EBITDA | 258 | 258 | 258 | ||||
| (=) Implied Enterprise Value | 1,986 | 2,091 | 2,195 | ||||
| (-) Non-shareholder Claims * | (418) | (418) | (418) | ||||
| (=) Equity Value | 1,568 | 1,673 | 1,777 | ||||
| (/) Shares Outstanding | 47.5 | 47.5 | 47.5 | ||||
| Implied Value Range | 33.01 | 35.21 | 37.41 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 33.01 | 35.21 | 37.41 | 25.12 | |||
| Upside / (Downside) | 31.4% | 40.2% | 48.9% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | ASRT | XERS | SUPN | PBH | CORT | AMPH | |
| Enterprise Value | (2) | 925 | 1,388 | 5,087 | 7,245 | 1,611 | |
| (+) Cash & Short Term Investments | 100 | 72 | 454 | 51 | 383 | 222 | |
| (+) Investments & Other | 0 | 0 | 0 | 0 | 220 | 11 | |
| (-) Debt | (40) | (271) | (34) | (1,027) | (7) | (651) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 58 | 726 | 1,808 | 4,111 | 7,841 | 1,193 | |
| (/) Shares Outstanding | 95.8 | 156.4 | 55.8 | 49.5 | 106.0 | 47.5 | |
| Implied Stock Price | 0.61 | 4.64 | 32.39 | 82.98 | 73.94 | 25.12 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.61 | 4.64 | 32.39 | 82.98 | 73.94 | 25.12 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |